Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | POLG | P54098 | 3/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314097 | 0.89 | FGFR1 (0.42) | FGFR1SLC22A6POLBHPRT1 | |
| SCHEMBL6319799 | 0.89 | FGFR1 (0.52) | FGFR1SLC22A6POLA1HPRT1 | |
| SCHEMBL13714883 | 0.74 | FGFR1 (0.40) | FGFR1SLC22A6POLBPOLGPOLA1 | |
| SCHEMBL6904634 | 0.74 | FGFR1 (0.50) | FGFR1SLC22A6POLA1HPRT1 | |
| SCHEMBL15531740 | 0.72 | POLB (0.56) | FGFR1SLC22A6POLBPOLGPOLA1 | |
| SCHEMBL13805641 | 0.71 | FGFR1 (0.79) | FGFR1SLC22A6POLBPOLGHPRT1 | |
| SCHEMBL5720716 | 0.68 | FGFR1 (0.44) | FGFR1SLC22A6POLBPOLGHPRT1 | |
| SCHEMBL3860484 | 0.67 | FGFR1 (0.50) | FGFR1SLC22A6HPRT1 | |
| SCHEMBL16037312 | 0.67 | FGFR1 (0.50) | FGFR1SLC22A6POLBPOLGPOLA1 | |
| Cidofovir Diposphate SCHEMBL29390031 | 0.67 | FGFR1 (0.74) | FGFR1SLC22A6POLBPOLGPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050033051-A1 | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033051-A1 | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases | NSUN2, RNASEH1, POLR2H | FGFR1 4136/4885SLC22A6 4025/4885POLB 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.